Education & Training
University of Missouri School of Medicine
- University of Missouri School of Medicine GME
Pulmonary and Critical Care Medicine
- The University of Iowa
MU Health Care participates with most major managed care organizations. To find out whether MU Health Care is a participating provider in your insurance plan or network, or for information on co-payments and deductibles, please contact your insurance carrier directly.
In the News
Dr. Holliday brings a clinical and research focus on pulmonary disease, specifically in cystic fibrosis, to the School of Medicine and currently directs MU Health Care’s cystic fibrosis center. He has a broad basic science and clinical research background in pulmonary medicine with training ranging from airway pH studies and immunofluorescence staining on airway epithelial cell cultures and porcine animal models, to pilot clinical studies looking at the effects of alkalinization of the upper airways on the underlying microbiome. Dr. Holliday’s primary research interest is the effects of alkalinization on airway innate host defense and has presented his findings at multiple national conferences and published his research. Dr. Holliday recently presented three abstracts at the North American Cystic Fibrosis Conference about outcomes in patients at the University of Missouri adult Cystic Fibrosis center after starting Elexacaftor-Tezacaftor-Ivacaftor.
Since his initial training, Dr. Holliday has also found interest in the long-term effects of cystic fibrosis transmembrane receptor (CFTR) modulators and helped complete a five-year longitudinal study looking at the effects at one of the first modulators, Ivacaftor, on CT pulmonary imaging and pulmonary function testing outcomes. This interest continued at the University of Missouri, with a more recent project looking at the effects of the newest CFTR modulator, Trikafta, on respiratory bacterial cultures, pulmonary function testing and imaging. Connecting most projects to date is an underlying interest in the interaction between the innate immune system of the lungs and bacterial/viral pathogens. Through his multiple experiences he has developed the skills to oversee clinical translational projects and collaborated with other researchers internally and externally.
This includes successfull collaborations with other researchers at the University of Iowa and University of Washington on previous projects including the THAM nasal pilot study and long-term effects of Ivacaftor study. Dr. Holliday is currently collaborating within the University of Missouri campus with Dr. Robert Thomen in the department of Radiology looking at MRI xenon gas ventilation scans in patients with Cystic Fibrosis and Dr. Adam Schrum in the department of Molecular Microbiology and Immunology on the effects of inhaled dornase alfa in patients with severe COVID-19.
- Effects of Tham Nasal Alkalinization on Airway Microbial Communities: A Pilot Study in Non-CF and CF Adults
Holliday, Z.M.; Launspach, J.L.; Durairaj, L.; Singh, P.K.; Zabner, J.; Stoltz, D.A.
Ann Otol Rhinol Laryngol. 2022 Sep;131(9):1013-1020. doi: 10.1177/00034894211051814. Epub 2021 Oct 21.PMID: 34674574
- Neutrophils and secondary infections in COVID-19 induced acute respiratory distress syndrome
Holliday, Z.M.; Alnijoumi, M.M.; Reed, M.A.; Earhart, A.P.; Schrum, A.G.; Allen, L.-A.H.; Krvavac, A.
New Microbes New Infect. 2021 Nov;44:100944. doi: 10.1016/j.nmni.2021.100944. Epub 2021 Sep 21.PMID: 34567574 Free PMC article
- Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
Holliday, Z.M.; Earhart, A.P.; Alnijoumi, M.M.; Krvavac, A.; Allen, L.-A.H.; Schrum, A.G.
Front Immunol. 2021 Oct 20;12:714833. doi: 10.3389/fimmu.2021.714833. eCollection 2021.PMID: 34745093 Free PMC article. Clinical Trial.
- Oral probiotics in coronavirus disease 2019: connecting the gut–lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials
Baindara, P.; Chakraborty, R.; Holliday, Z.M.; Mandal, S.M.; Schrum, A.G.
New Microbes New Infect. 2021 Mar;40:100837. doi: 10.1016/j.nmni.2021.100837. Epub 2021 Jan 6.PMID: 33425362 Free PMC article.
- Increased Incidence, Morbidity, and Mortality in Human Coronavirus NL63 Associated with ACE Inhibitor Therapy and Implication in SARS-CoV-2 (COVID-19)
Krvavac, A.; Patel, T.P.; Karle, E.M.; Epstein, N.B.; Reznikov, E.A.; Gates, L.G.; Holliday, Z.M.
Mo Med. 2020 Jul-Aug;117(4):346-354.PMID: 32848272 Free PMC article.
- Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
Earhart, A.P.; Holliday, Z.M.; Hofmann, H.V.; Schrum, A.G.
New Microbes New Infect. 2020 Apr 30;35:100689. doi: 10.1016/j.nmni.2020.100689. eCollection 2020 May.PMID: 32355564 Free PMC article.